Valiant Laboratories Ltd. (IN:VALIANTLAB)
:VALIANTLAB
Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹114.72
Previous CloseN/A
Volume41.92K
Average Volume (3M)1.58K
Market Cap
₹4.04B
Enterprise Value₹4.52B
Total Cash (Recent Filing)₹629.06M
Total Debt (Recent Filing)₹537.68M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Leverage And Sizable Equity BaseA large equity base versus modest debt provides structural financial flexibility: it supports ongoing operations, helps absorb cyclical API demand, and reduces near-term refinancing risk. This enduring balance-sheet strength can fund selective investment or cushion downturns without heavy leverage.
Strong FY2026 Revenue ReboundA 29.2% revenue rebound after prior declines signals recovering end-market demand and potential capacity utilization gains. Sustained top-line recovery underpins gross profit improvement and creates a clearer path to regain consistent operating profitability if margins and cash conversion stabilize.
Established API Manufacturing B2B BusinessSupplying APIs to formulators and finished-dosage manufacturers is a structurally resilient B2B model: recurring demand, technical/regulatory entry requirements, and quality expectations favor incumbent manufacturers and support steady order flow when regulatory compliance and customer relationships are maintained.
Bears Say
Weak Operating And Free Cash FlowSustained negative operating and free cash flow forces reliance on external funding for working capital and investments, constrains reinvestment and reduces optionality. Persistent cash burn raises execution risk and limits the company's ability to self-fund growth or return capital to shareholders over the medium term.
Recent Unprofitable Operating PerformanceA swing from prior multi-year profits to losses and near-zero operating profit undermines durable earnings power. This volatility suggests margin pressure or cost structure issues that, unless resolved, will impair the firm's ability to generate consistent earnings and to build retained earnings for longer-term investments.
Declining Returns On EquityA sizable equity base that is not delivering positive returns is a structural concern: capital efficiency is weak, creating an opportunity cost for shareholders and limiting the firm's ability to self-fund expansion. Persistently low or negative ROE pressures long-term value creation and allocation decisions.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹114.72 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹4.04B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 87 days.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on May 14, 2026. The company reported ₹0.32 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.32.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of ₹0.32 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.028%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Alpa Laboratories Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Krebs Biochemicals & Industries Ltd.
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―